一分钟看懂
这是一项关于淋巴瘤的III 期研究，登记的药物或干预包括Zilovertamab vedotin；Rituximab；Cyclophosphamide；Doxorubicin；Rituximab Biosimilar；Prednisone；Prednisolone；Vincristine；Rescue medication；Methy，当前状态为招募中。登记地点显示中国合肥、北京、重庆、福州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Zilovertamab vedotin；Rituximab；Cyclophosphamide；Doxorubicin；Rituximab Biosimilar；Prednisone；Prednisolone；Vincristine；Rescue medication；Methylprednisolone · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui Provincial Cancer Hospital ( Site 3124) · 合肥
- Peking University Third Hospital ( Site 3102) · 北京
- Beijing Cancer Hospital ( Site 3101) · 北京
- Chongqing Cancer Hospital ( Site 3113) · 重庆
- Fujian Provincial Cancer Hospital. ( Site 3119) · 福州
- The First Affiliated Hospital of Xiamen University ( Site 3120) · 厦门
- Sun Yat-sen University Cancer Center ( Site 3121) · 广州
- Zhujiang Hospital of Southern Medical University ( Site 3122) · 广州
- Affiliated Cancer Hospital of Guangxi Medical University ( Site 3123) · 南宁
- The Affiliated Hospital of Guizhou Medical University ( Site 3112) · 贵阳
- Hubei Cancer Hospital ( Site 3125) · 武汉
- Affiliated Hospital of Nantong University ( Site 3117) · 南通
- Jiangxi Cancer Hospital ( Site 3118) · 南昌
- The First Hospital Of Jilin University ( Site 3103) · 长春
- Shandong Cancer Hospital ( Site 3108) · 济南
- LinYi Cancer Hospital ( Site 3104) · 临沂
- Fudan University Shanghai Cancer Center ( Site 3115) · 上海
- Shanxi Cancer Hospital ( Site 3106) · 太原
- 1st Affil Hosp of Med College of Xi'an Jiaotong University ( Site 3107) · 西安
- Sichuan Cancer Hospital. ( Site 3111) · 成都
- West China Hospital, Sichuan University ( Site 3110) · 成都
- Institute of Hematology and Blood Diseases Hosp CAMS&PUMC ( Site 3105) · 天津
- Yunnan Province Cancer Hospital ( Site 3109) · 昆明
- The First Affiliated Hospital, Zhejiang Medical University ( Site 3116) · 杭州
公开的入选条件
- * Has histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, based on local testing according to the WHO classification of neoplasms of the hematopoietic and lymphoid tissues
- * Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale
- * Has received no prior treatment for their DLBCL
- * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before randomization
- * Has an ejection fraction ≥45% as determined by either echocardiogram (ECHO) or multigated acquisition (MUGA)
- * Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART)
- * Who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization
- * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06717347；登记信息更新于 2026-09-17。